← Eichor
Condition: Durvalumab Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Durvalumab

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic C
NA · 8 location(s) · Aichi Medical University · NCT07235007Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepato
Phase 2 · 4 location(s) · Riboscience, LLC. · NCT07175441Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immun
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06694454BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
Phase 2 · 33 location(s) · SCRI Development Innovations, LLC · NCT06773910A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immu
Phase 2 · 11 location(s) · Canadian Cancer Trials Group · NCT03847649AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR
Phase 2 · 1 location(s) · Gruppo Oncologico Italiano di Ricerca Clinica · NCT06464068Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metas
Phase 2 · 1 location(s) · Fudan University · NCT06591650Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract
Phase 2 · 9 location(s) · Centre Hospitalier Universitaire de Nīmes · NCT04617756Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary
Phase 2/Phase 3 · 258 location(s) · National Cancer Institute (NCI) · NCT04628767Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance
Phase N/A · 1 location(s) · AstraZeneca · NCT06995833Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Out
Phase 2 · 58 location(s) · National Cancer Institute (NCI) · NCT06050252Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
Phase 2 · 3 location(s) · Anwaar Saeed · NCT06698250Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC
Phase 2 · 5 location(s) · University Hospital, Bonn · NCT06810609Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherap
Phase 2 · 6 location(s) · University of Kansas Medical Center · NCT04992780Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced
Phase 2 · 1 location(s) · West China Hospital · NCT06859684Durvalumab and Tremelimumab in Resectable HCC
Phase 2 · 3 location(s) · University Health Network, Toronto · NCT05440864FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of P
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07012798Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy
Phase 2 · 1 location(s) · Asan Medical Center · NCT05222971Durvalumab as Consolidation for Patients LS-SCLC
Phase 2 · 2 location(s) · Qian Chu · NCT07055581Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment
Phase 2 · 7 location(s) · Centre Leon Berard · NCT02029001Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT03907475IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Phase 2 · 30 location(s) · Innate Pharma · NCT05742607A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine i
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07679399Montreal Immune-Related Adverse Events (MIRAE) Study
Phase N/A · 1 location(s) · Sir Mortimer B. Davis - Jewish General Hospital · NCT05139706Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies
Phase 1 · 1 location(s) · National University Hospital, Singapore · NCT03772561Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
Phase 2/Phase 3 · 14 location(s) · Leiden University Medical Center · NCT05255653Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab
Phase 4 · 1 location(s) · Idris Bahce · NCT06908070RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
Phase 2 · 10 location(s) · Masonic Cancer Center, University of Minnesota · NCT04105270A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Phase 1/Phase 2 · 13 location(s) · IDEAYA Biosciences · NCT07174583A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT
Phase 3 · 50 location(s) · Merck Sharp & Dohme LLC · NCT07554339
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.